pixlbio combines human-relevant iPSC-derived cell models with AI-powered phenomics to turn cellular images into predictive, reproducible insight for drug discovery, development, and safety assessment. Using high-throughput imaging and cell painting, pixlbio captures rich phenotypic signatures and applies AI-first analytics to reveal subtle biology that’s hard to detect otherwise - supporting compound prioritization, hypothesis testing, and de-risking decisions earlier in R&D. Results are delivered through our proprietary SaaS platform with dashboards and structured data packages, with options for tailored studies and CRISPR-engineered genotypes.